A practical reference on Angiotensin IV analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Ampicillin/sulbactam is a fixed-dose combination medication of the common penicillin-derived antibiotic ampicillin and sulbactam, an inhibitor of bacterial beta-lactamase. Two different forms of the drug exist. The first, developed in 1987 and marketed in the United States under the brand name Unasyn, generic only outside the United States, is an intravenous antibiotic. The second, an oral form called sultamicillin, is marketed under the brand name Ampictam outside the United States, and generic only in the United States. Ampicillin/sulbactam is used to treat infections caused by bacteria resistant to beta-lactam antibiotics. Sulbactam blocks the enzyme which breaks down ampicillin and thereby allows ampicillin to attack and kill the bacteria.
Member American Academy of Arts & Sciences (2025) Member, The World Academy of Science (2025) Founders Award, Controlled Release Society (2025) Distinguished Scientist Award, American Association of Pharmaceutical Scientists (2024) Doing a World of Good Medal (2023) BIOS- Top 50 Lifescience Entrepreneur List (2022) Kydonieus Award, Controlled Release Society (2020) Clemson Award, Society for Biomaterials (2017) Member, National Academy of Medicine (NAM) (2016) Fellow, Biomedical Engineering Society (BMES) (2015) Fellow, American Association of Pharmaceutical Scientists (AAPS) (2015) Fellow, Controlled Release Society (CRS) (2015) Andreas Acrivos Award for Professional Progress, American Institute of Chemical Engineers (AIChE) (2015) Member, National Academy of Engineering (NAE) (2015) Fellow, National Academy of Inventors (NAI) (2013) Fellow, American Association for the Advancement of Science (AAAS) (2012) Fellow, American Institute for Medical and Biological Engineering (AIMBE) (2010) Controlled Release Society’s Young Scientist Award (2008) American Institute of Chemical Engineers Allan P. Colburn award (2005) Selection by MIT's Technology Review Magazine as one of the world's top Innovators Under 35 (1999)
While tyrosine phosphorylation is found in relatively low abundance, it is well studied due to the ease of purification of phosphotyrosine using antibodies. Receptor tyrosine kinases are an important family of cell surface receptors involved in the transduction of extracellular signals such as hormones, growth factors, and cytokines. Binding of a ligand to a monomeric receptor tyrosine kinase stabilizes interactions between two monomers to form a dimer, after which the two bound receptors phosphorylate tyrosine residues in trans. Phosphorylation and activation of the receptor activates a signaling pathway through enzymatic activity and interactions with adaptor proteins. Signaling through the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase, is critical for the development of multiple organ systems including the skin, lung, heart, and brain. Excessive signaling through the EGFR pathway is found in many human cancers.
Sources: en.wikipedia.org
== Upcoming Peptide Facility == Neuland Laboratories is set to commission a new commercial peptide manufacturing facility at its 17- acre Bonthapally manufacturing campus in the summer of 2026. The project is part of a phased expansion, with additional capacity planned in line with growing client demand. The first of four modules is expected to be operational by mid-2026, adding commercial scale capabilities to its existing peptide manufacturing infrastructure. The new peptide manufacturing facility will feature digitalized operations supported by distributed control system (DCS) automation and electronic batch‑record platforms. It is also designed with expanded purification and drying infrastructure, including multi‑column preparative HPLC systems, large‑scale lyophilizers, enhanced solvent‑handling capabilities, and upgraded waste‑management processes. These features are intended to support consistent batch quality and more efficient production cycles.
Ethanol is only one of several types of chemical alcohols, and has a variety of analogues. Most other alcohols are considered poisonous. In general, higher alcohols are less toxic. Alcoholic beverages are sometimes laced with toxic alcohols. The toxicity of isopropyl alcohol is about twice that of ethanol; a mild, brief exposure to isopropyl alcohol is unlikely to cause any serious harm, although ingesting significant quantities can lead to vomiting, abdominal pain, and internal bleeding. Methanol is the most toxic alcohol. Ingestion of as little as 3.16 grams of methanol can cause irreversible optic nerve damage, and the oral LD50 for humans is estimated to be 56.2 grams. Many methanol poisoning incidents have occurred through history. n-Butanol is reported to produce similar effects to those of ethanol and relatively low toxicity (one-sixth of that of ethanol in one rat study). However, its vapors can produce eye irritation, and inhalation can cause pulmonary edema. Acetone (propanone) is a ketone rather than an alcohol, and is reported to produce similar toxic effects; it can be extremely damaging to the cornea. Although ethanol is the most prevalent alcohol in alcoholic beverages, alcoholic beverages contain several types of psychoactive alcohols, that are categorized as primary, secondary, or tertiary. Primary and secondary alcohols, are oxidized to aldehydes, and ketones, respectively, while tertiary alcohols are generally resistant to oxidation. The Lucas test differentiates between primary, secondary, and tertiary alcohols.
=== January === 2 January – Former Deputy Prime Minister Sir Nick Clegg announces he is standing down as Meta's president of global affairs after almost seven years. Twenty Labour Party councillors on Broxtowe Borough Council in Nottinghamshire have resigned from Labour in protest at the direction of the party under Keir Starmer and will sit as independents. Graham Sheldon resigns as leader of Oldham Council's Conservatives, and from the Conservative Party itself, after police were called to a heated council meeting on 18 December. Kemi Badenoch calls for a public inquiry into grooming gangs. 3 January – The UK government announces that the plans for reforms to social care in England may not be published until 2028, or later. Zoe Hughes, a transgender member of Exeter City council, quits the Labour Party in a row over transgender issues. 4 January – Reform UK leader Nigel Farage seeks to distance himself from Elon Musk's call for far-right activist Tommy Robinson to be released from prison. At Reform's East of England Conference in Chelmsford, Farage threatens to target Conservative leader Kemi Badenoch's North West Essex seat over her allegations his party's membership figures are weak, and seems to show that the party now has 170,000 members. 5 January – In a post on Twitter, Elon Musk says that Nigel Farage "doesn't have what it takes" to lead Reform UK, remarks that Farage says stem from a disagreement over Musk's support for far-right activist Tommy Robinson.
Sources: en.wikipedia.org
=== Reaction === Limulus clotting enzyme uses 2H2O to cleave the Arg18-Gly19 and Arg46-Thr47 linkages in coagulogen, forming coagulin + two peptide products. This process activates coagulin, allowing it to gel and form clots around bacterial invaders. The reaction is hydrolytic and catalyzed by the His-Asp-Ser triad in the active site. The hydroxyl group in serine acts as a nucleophile, attacking the carbonyl carbon in the peptide bond. Histidine’s nitrogen atom accepts the hydrogen from serine’s hydroxyl group to make serine a stronger nucleophile. Aspartic acid forms hydrogen bonds with histidine to make this nitrogen atom more electronegative and therefore more likely to accept the hydrogen. The nucleophilic attack results in the peptide bond breaking, allowing one peptide fragment to be released. A water molecule is then deprotonated by the histidine. The resulting hydroxyl acts as a nucleophile to break the bond between the serine and the carbonyl, releasing the rest of the protein. The process is then repeated at the other peptide bond.
== Consciousness and dreaming == Initially, dreaming was thought to only occur in rapid eye movement sleep, though it is now known that dreaming may also occur during slow-wave sleep. Delta waves and delta wave activity are marked, in most people, by an apparently unconscious state, and the loss of physical awareness as well as the "iteration of information". Delta wave activity has also been purported to aid in declarative and explicit memory formation.
=== B cell epitopes === There are two main methods of epitope mapping: either structural or functional studies. Methods for structurally mapping epitopes include X-ray crystallography, nuclear magnetic resonance, and electron microscopy. X-ray crystallography of Ag-Ab complexes is considered an accurate way to structurally map epitopes. Nuclear magnetic resonance can be used to map epitopes by using data about the Ag-Ab complex. This method does not require crystal formation but can only work on small peptides and proteins. Electron microscopy is a low-resolution method that can localize epitopes on larger antigens like virus particles. Methods for functionally mapping epitopes often use binding assays such as western blot, dot blot, and/or ELISA to determine antibody binding. Competition methods look to determine if two monoclonal antibodies (mABs) can bind to an antigen at the same time or compete with each other to bind at the same site. Another technique involves high-throughput mutagenesis, an epitope mapping strategy developed to improve rapid mapping of conformational epitopes on structurally complex proteins. Mutagenesis uses randomly/site-directed mutations at individual residues to map epitopes. B-cell epitope mapping can be used for the development of antibody therapeutics, peptide-based vaccines, and immunodiagnostic tools.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.